Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 15 Neoplasm Metastasis 3 HER2-positive Breast Cancer 2 Brain Neoplasms 2 Stomach Neoplasms 1 Solid Cancer 1 Recurrence 1 Rectal Neoplasms 1 Neoplasms 1 Meningeal Neoplasms 1 Meningeal Carcinomatosis 1 Liver Neoplasms 1 Inflammatory Breast Neoplasms 1 HER2-positive Early Breast Cancer 1 Gastrointestinal Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Carcinoma 1 Cancer Related Cognitive Decline 1 Breast Neoplasms, Male 1 Breast Diseases 1 Biliary Tract Neoplasms 1 Bile Duct Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cancer Related Cognitive Decline × pertuzumab × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡